Interest in harnessing natural killer (NK) cells for cancer immunotherapy is rapidly growing. However, efficacy of NK cell-based immunotherapy remains limited in most trials. Strategies to augment the killing efficacy of NK cells are thus much needed. In the current study, we found that mitochondr...
Interest in harnessing natural killer (NK) cells for cancer immunotherapy is rapidly growing. However, efficacy of NK cell-based immunotherapy remains limited in most trials. Strategies to augment the killing efficacy of NK cells are thus much needed. In the current study, we found that mitochondr...
Therefore, PARPi-based immunotherapy may be useful for CC [36]. However, in clinical practice, targeted therapy fails to work in the long run due to tumors not responding to the drugs or the person who initially responded having eventually developed acquired resistance to the drugs [37]. ...
Advancing cell-based cancer immunotherapy through stem cell engineering. Cell Stem Cell 30, 592–610 (2023). Article CAS PubMed PubMed Central Google Scholar Gattinoni, L., Speiser, D. E., Lichterfeld, M. & Bonini, C. T memory stem cells in health and disease. Nat. Med. 23, 18–...